NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial And New Exploratory Analysis From Completed Phase 1 Head And Neck Cancer Trial
Portfolio Pulse from Benzinga Newsdesk
Nanobiotix has announced updated preliminary results from its Phase 1 pancreatic cancer trial and new exploratory analysis from its completed Phase 1 head and neck cancer trial. The ongoing Phase 1 study of NBTXR3 in locally advanced pancreatic cancer established a favorable safety profile and recommended dose. An exploratory analysis of completed Study 102 showed a positive correlation between Objective Response to RT-activated NBTXR3 and the extension of Overall Survival for elderly, frail patients with head and neck cancer.
October 23, 2023 | 7:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nanobiotix's ongoing Phase 1 study of NBTXR3 in pancreatic cancer and completed Study 102 in head and neck cancer have shown promising results, potentially positively impacting the company's stock.
The positive preliminary results from Nanobiotix's Phase 1 trials of NBTXR3 in pancreatic and head and neck cancer suggest that the drug is effective and safe. This could increase investor confidence in the company and drive up its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100